nodes	percent_of_prediction	percent_of_DWPC	metapath
Gefitinib—EGFR—bile duct cancer	0.813	1	CbGaD
Gefitinib—ORM1—bile—bile duct cancer	0.00975	0.173	CbGeAlD
Gefitinib—Lapatinib—ERBB2—bile duct cancer	0.00417	0.327	CrCbGaD
Gefitinib—Afatinib—ERBB2—bile duct cancer	0.00296	0.232	CrCbGaD
Gefitinib—ORM1—gall bladder—bile duct cancer	0.00271	0.048	CbGeAlD
Gefitinib—ALB—gall bladder—bile duct cancer	0.00237	0.0421	CbGeAlD
Gefitinib—CSNK1E—pancreas—bile duct cancer	0.00231	0.0409	CbGeAlD
Gefitinib—ERBB3—pancreas—bile duct cancer	0.00222	0.0395	CbGeAlD
Gefitinib—MKNK2—pancreas—bile duct cancer	0.00211	0.0375	CbGeAlD
Gefitinib—IRAK1—pancreas—bile duct cancer	0.00211	0.0375	CbGeAlD
Gefitinib—SBK1—lymph node—bile duct cancer	0.00204	0.0361	CbGeAlD
Gefitinib—Lapatinib—EGFR—bile duct cancer	0.00197	0.155	CrCbGaD
Gefitinib—CHEK2—lymph node—bile duct cancer	0.00177	0.0315	CbGeAlD
Gefitinib—EGFR—liver—bile duct cancer	0.00153	0.0271	CbGeAlD
Gefitinib—CSNK1E—liver—bile duct cancer	0.00147	0.026	CbGeAlD
Gefitinib—IRAK4—liver—bile duct cancer	0.00144	0.0256	CbGeAlD
Gefitinib—ERBB3—liver—bile duct cancer	0.00142	0.0251	CbGeAlD
Gefitinib—Afatinib—EGFR—bile duct cancer	0.0014	0.11	CrCbGaD
Gefitinib—MKNK2—liver—bile duct cancer	0.00135	0.0239	CbGeAlD
Gefitinib—IRAK1—liver—bile duct cancer	0.00135	0.0239	CbGeAlD
Gefitinib—MKNK1—liver—bile duct cancer	0.00133	0.0236	CbGeAlD
Gefitinib—EGFR—lymph node—bile duct cancer	0.00117	0.0208	CbGeAlD
Gefitinib—CSNK1E—lymph node—bile duct cancer	0.00112	0.02	CbGeAlD
Gefitinib—IRAK4—lymph node—bile duct cancer	0.00111	0.0197	CbGeAlD
Gefitinib—STK10—liver—bile duct cancer	0.00109	0.0194	CbGeAlD
Gefitinib—ERBB3—lymph node—bile duct cancer	0.00109	0.0193	CbGeAlD
Gefitinib—MKNK2—lymph node—bile duct cancer	0.00103	0.0183	CbGeAlD
Gefitinib—IRAK1—lymph node—bile duct cancer	0.00103	0.0183	CbGeAlD
Gefitinib—MKNK1—lymph node—bile duct cancer	0.00102	0.0181	CbGeAlD
Gefitinib—Erlotinib—EGFR—bile duct cancer	0.000988	0.0775	CrCbGaD
Gefitinib—MAP2K5—liver—bile duct cancer	0.000977	0.0173	CbGeAlD
Gefitinib—STK10—lymph node—bile duct cancer	0.000839	0.0149	CbGeAlD
Gefitinib—ORM1—liver—bile duct cancer	0.000793	0.0141	CbGeAlD
Gefitinib—MAP2K5—lymph node—bile duct cancer	0.000749	0.0133	CbGeAlD
Gefitinib—ALB—liver—bile duct cancer	0.000696	0.0123	CbGeAlD
Gefitinib—CYP3A5—pancreas—bile duct cancer	0.000694	0.0123	CbGeAlD
Gefitinib—Vandetanib—EGFR—bile duct cancer	0.000651	0.051	CrCbGaD
Gefitinib—Bosutinib—EGFR—bile duct cancer	0.000609	0.0477	CrCbGaD
Gefitinib—ORM1—lymph node—bile duct cancer	0.000608	0.0108	CbGeAlD
Gefitinib—CYP2C19—liver—bile duct cancer	0.00056	0.00994	CbGeAlD
Gefitinib—ALB—lymph node—bile duct cancer	0.000533	0.00947	CbGeAlD
Gefitinib—ABCG2—liver—bile duct cancer	0.000475	0.00844	CbGeAlD
Gefitinib—CYP1A1—liver—bile duct cancer	0.000451	0.00801	CbGeAlD
Gefitinib—CYP3A5—liver—bile duct cancer	0.000441	0.00783	CbGeAlD
Gefitinib—CYP2C9—liver—bile duct cancer	0.000434	0.00771	CbGeAlD
Gefitinib—ABCB1—pancreas—bile duct cancer	0.000368	0.00654	CbGeAlD
Gefitinib—ABCG2—lymph node—bile duct cancer	0.000364	0.00647	CbGeAlD
Gefitinib—CYP1A1—lymph node—bile duct cancer	0.000346	0.00614	CbGeAlD
Gefitinib—CYP3A4—liver—bile duct cancer	0.000331	0.00588	CbGeAlD
Gefitinib—CYP2D6—liver—bile duct cancer	0.000326	0.00578	CbGeAlD
Gefitinib—ABCB1—liver—bile duct cancer	0.000234	0.00416	CbGeAlD
Gefitinib—ABCB1—lymph node—bile duct cancer	0.00018	0.00319	CbGeAlD
Gefitinib—IRAK1—Signaling by NGF—IL6—bile duct cancer	4.26e-05	0.000361	CbGpPWpGaD
Gefitinib—ALB—Selenium Micronutrient Network—IL6—bile duct cancer	4.21e-05	0.000357	CbGpPWpGaD
Gefitinib—EGFR—DAP12 interactions—IL6—bile duct cancer	4.18e-05	0.000354	CbGpPWpGaD
Gefitinib—EGFR—Fc epsilon receptor (FCERI) signaling—IL6—bile duct cancer	4.18e-05	0.000354	CbGpPWpGaD
Gefitinib—EGFR—Signaling by FGFR in disease—IL6—bile duct cancer	4.18e-05	0.000354	CbGpPWpGaD
Gefitinib—ERBB3—Innate Immune System—NRAS—bile duct cancer	4.16e-05	0.000353	CbGpPWpGaD
Gefitinib—EGFR—Axon guidance—MMP9—bile duct cancer	4.15e-05	0.000351	CbGpPWpGaD
Gefitinib—EGFR—Signaling by EGFR—IL6—bile duct cancer	4.14e-05	0.000351	CbGpPWpGaD
Gefitinib—EGFR—Focal Adhesion—HRAS—bile duct cancer	4.12e-05	0.00035	CbGpPWpGaD
Gefitinib—EGFR—Signaling by EGFR in Cancer—IL6—bile duct cancer	4.1e-05	0.000348	CbGpPWpGaD
Gefitinib—EGFR—Signaling by PDGF—IL6—bile duct cancer	4.09e-05	0.000346	CbGpPWpGaD
Gefitinib—EGFR—Signaling by NGF—NRAS—bile duct cancer	4.07e-05	0.000344	CbGpPWpGaD
Gefitinib—EGFR—B Cell Activation—HRAS—bile duct cancer	4.04e-05	0.000342	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—TGFBR2—bile duct cancer	4.04e-05	0.000342	CbGpPWpGaD
Gefitinib—ERBB3—Adaptive Immune System—NRAS—bile duct cancer	4e-05	0.000339	CbGpPWpGaD
Gefitinib—IRAK4—Immune System—ERBB2—bile duct cancer	4e-05	0.000339	CbGpPWpGaD
Gefitinib—ALB—Transmembrane transport of small molecules—SLC5A5—bile duct cancer	3.96e-05	0.000335	CbGpPWpGaD
Gefitinib—EGFR—Developmental Biology—MMP2—bile duct cancer	3.94e-05	0.000334	CbGpPWpGaD
Gefitinib—ERBB3—Disease—NOS2—bile duct cancer	3.91e-05	0.000332	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—GNAS—bile duct cancer	3.89e-05	0.00033	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—TGFBR2—bile duct cancer	3.89e-05	0.00033	CbGpPWpGaD
Gefitinib—EGFR—NGF signalling via TRKA from the plasma membrane—HRAS—bile duct cancer	3.87e-05	0.000328	CbGpPWpGaD
Gefitinib—CSNK1E—Disease—ERBB2—bile duct cancer	3.86e-05	0.000327	CbGpPWpGaD
Gefitinib—IRAK4—Innate Immune System—HRAS—bile duct cancer	3.82e-05	0.000324	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—SMAD4—bile duct cancer	3.82e-05	0.000324	CbGpPWpGaD
Gefitinib—ERBB3—Innate Immune System—EGFR—bile duct cancer	3.79e-05	0.000322	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—IDH2—bile duct cancer	3.79e-05	0.000321	CbGpPWpGaD
Gefitinib—MKNK1—Disease—NRAS—bile duct cancer	3.78e-05	0.00032	CbGpPWpGaD
Gefitinib—CSNK1E—Disease—PTGS2—bile duct cancer	3.78e-05	0.00032	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—GNAS—bile duct cancer	3.75e-05	0.000318	CbGpPWpGaD
Gefitinib—EGFR—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—bile duct cancer	3.74e-05	0.000317	CbGpPWpGaD
Gefitinib—ABCB1—Integrated Pancreatic Cancer Pathway—ERBB2—bile duct cancer	3.73e-05	0.000316	CbGpPWpGaD
Gefitinib—EGFR—NGF signalling via TRKA from the plasma membrane—IL6—bile duct cancer	3.7e-05	0.000314	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—SMAD4—bile duct cancer	3.68e-05	0.000312	CbGpPWpGaD
Gefitinib—EGFR—Axon guidance—NRAS—bile duct cancer	3.68e-05	0.000312	CbGpPWpGaD
Gefitinib—IRAK4—Innate Immune System—IL6—bile duct cancer	3.66e-05	0.00031	CbGpPWpGaD
Gefitinib—ERBB3—Adaptive Immune System—EGFR—bile duct cancer	3.64e-05	0.000309	CbGpPWpGaD
Gefitinib—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—bile duct cancer	3.64e-05	0.000309	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—FAR2—bile duct cancer	3.61e-05	0.000306	CbGpPWpGaD
Gefitinib—ERBB3—Innate Immune System—KRAS—bile duct cancer	3.58e-05	0.000304	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—IDH2—bile duct cancer	3.58e-05	0.000304	CbGpPWpGaD
Gefitinib—EGFR—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—bile duct cancer	3.58e-05	0.000303	CbGpPWpGaD
Gefitinib—ALB—Hemostasis—GNAS—bile duct cancer	3.55e-05	0.000301	CbGpPWpGaD
Gefitinib—EGFR—Signaling by GPCR—GNAS—bile duct cancer	3.54e-05	0.0003	CbGpPWpGaD
Gefitinib—MKNK1—Disease—TGFB1—bile duct cancer	3.51e-05	0.000298	CbGpPWpGaD
Gefitinib—EGFR—Signaling by NGF—KRAS—bile duct cancer	3.5e-05	0.000296	CbGpPWpGaD
Gefitinib—MKNK1—Signaling Pathways—ERBB2—bile duct cancer	3.48e-05	0.000295	CbGpPWpGaD
Gefitinib—IRAK1—Innate Immune System—NRAS—bile duct cancer	3.47e-05	0.000294	CbGpPWpGaD
Gefitinib—ABCB1—Transmembrane transport of small molecules—SLC5A5—bile duct cancer	3.47e-05	0.000294	CbGpPWpGaD
Gefitinib—EGFR—Developmental Biology—ERBB2—bile duct cancer	3.45e-05	0.000292	CbGpPWpGaD
Gefitinib—MKNK1—Disease—EGFR—bile duct cancer	3.44e-05	0.000292	CbGpPWpGaD
Gefitinib—ERBB3—Adaptive Immune System—KRAS—bile duct cancer	3.44e-05	0.000292	CbGpPWpGaD
Gefitinib—ALB—Hemostasis—HGF—bile duct cancer	3.38e-05	0.000287	CbGpPWpGaD
Gefitinib—ALB—Metabolism—IDH2—bile duct cancer	3.27e-05	0.000277	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—IDH1—bile duct cancer	3.26e-05	0.000276	CbGpPWpGaD
Gefitinib—MKNK1—Disease—KRAS—bile duct cancer	3.25e-05	0.000276	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—TGFBR2—bile duct cancer	3.24e-05	0.000275	CbGpPWpGaD
Gefitinib—ERBB3—Immune System—ERBB2—bile duct cancer	3.19e-05	0.00027	CbGpPWpGaD
Gefitinib—EGFR—Axon guidance—KRAS—bile duct cancer	3.17e-05	0.000268	CbGpPWpGaD
Gefitinib—IRAK1—Innate Immune System—EGFR—bile duct cancer	3.16e-05	0.000268	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—GNAS—bile duct cancer	3.12e-05	0.000265	CbGpPWpGaD
Gefitinib—EGFR—Disease—TGFBR2—bile duct cancer	3.09e-05	0.000262	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—IDH1—bile duct cancer	3.08e-05	0.000261	CbGpPWpGaD
Gefitinib—EGFR—Immune System—HGF—bile duct cancer	3.08e-05	0.000261	CbGpPWpGaD
Gefitinib—ALB—Transmembrane transport of small molecules—GNAS—bile duct cancer	3.07e-05	0.00026	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—SMAD4—bile duct cancer	3.07e-05	0.00026	CbGpPWpGaD
Gefitinib—EGFR—Innate Immune System—ERBB2—bile duct cancer	3.05e-05	0.000258	CbGpPWpGaD
Gefitinib—ERBB3—Innate Immune System—HRAS—bile duct cancer	3.05e-05	0.000258	CbGpPWpGaD
Gefitinib—IRAK4—Immune System—NRAS—bile duct cancer	3.04e-05	0.000258	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—SLC5A5—bile duct cancer	3e-05	0.000254	CbGpPWpGaD
Gefitinib—IRAK1—Innate Immune System—KRAS—bile duct cancer	2.98e-05	0.000253	CbGpPWpGaD
Gefitinib—MKNK1—Signaling Pathways—MMP9—bile duct cancer	2.98e-05	0.000253	CbGpPWpGaD
Gefitinib—EGFR—Signaling by NGF—HRAS—bile duct cancer	2.97e-05	0.000252	CbGpPWpGaD
Gefitinib—EGFR—Developmental Biology—MMP9—bile duct cancer	2.96e-05	0.000251	CbGpPWpGaD
Gefitinib—ERBB3—Disease—ERBB2—bile duct cancer	2.94e-05	0.000249	CbGpPWpGaD
Gefitinib—CSNK1E—Disease—NRAS—bile duct cancer	2.94e-05	0.000249	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—IDH2—bile duct cancer	2.93e-05	0.000248	CbGpPWpGaD
Gefitinib—EGFR—Disease—SMAD4—bile duct cancer	2.93e-05	0.000248	CbGpPWpGaD
Gefitinib—EGFR—Adaptive Immune System—ERBB2—bile duct cancer	2.93e-05	0.000248	CbGpPWpGaD
Gefitinib—ERBB3—Adaptive Immune System—HRAS—bile duct cancer	2.93e-05	0.000248	CbGpPWpGaD
Gefitinib—ERBB3—Innate Immune System—IL6—bile duct cancer	2.92e-05	0.000247	CbGpPWpGaD
Gefitinib—ERBB3—Disease—PTGS2—bile duct cancer	2.88e-05	0.000244	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—IDH2—bile duct cancer	2.86e-05	0.000242	CbGpPWpGaD
Gefitinib—EGFR—Signaling by NGF—IL6—bile duct cancer	2.85e-05	0.000241	CbGpPWpGaD
Gefitinib—ALB—Metabolism—IDH1—bile duct cancer	2.81e-05	0.000238	CbGpPWpGaD
Gefitinib—IRAK4—Immune System—EGFR—bile duct cancer	2.77e-05	0.000235	CbGpPWpGaD
Gefitinib—MKNK1—Disease—HRAS—bile duct cancer	2.77e-05	0.000234	CbGpPWpGaD
Gefitinib—CSNK1E—Disease—TGFB1—bile duct cancer	2.73e-05	0.000231	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—ERBB2—bile duct cancer	2.71e-05	0.000229	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—IDH2—bile duct cancer	2.7e-05	0.000228	CbGpPWpGaD
Gefitinib—ABCB1—Transmembrane transport of small molecules—GNAS—bile duct cancer	2.69e-05	0.000228	CbGpPWpGaD
Gefitinib—EGFR—Axon guidance—HRAS—bile duct cancer	2.69e-05	0.000228	CbGpPWpGaD
Gefitinib—CSNK1E—Disease—EGFR—bile duct cancer	2.68e-05	0.000227	CbGpPWpGaD
Gefitinib—ALB—Platelet activation, signaling and aggregation—TGFB1—bile duct cancer	2.67e-05	0.000227	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—IDH2—bile duct cancer	2.67e-05	0.000227	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—ERBB2—bile duct cancer	2.65e-05	0.000225	CbGpPWpGaD
Gefitinib—MKNK1—Signaling Pathways—NRAS—bile duct cancer	2.65e-05	0.000224	CbGpPWpGaD
Gefitinib—MKNK1—Disease—IL6—bile duct cancer	2.65e-05	0.000224	CbGpPWpGaD
Gefitinib—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—bile duct cancer	2.63e-05	0.000223	CbGpPWpGaD
Gefitinib—EGFR—Developmental Biology—NRAS—bile duct cancer	2.63e-05	0.000222	CbGpPWpGaD
Gefitinib—IRAK4—Immune System—KRAS—bile duct cancer	2.62e-05	0.000222	CbGpPWpGaD
Gefitinib—ALB—Hemostasis—NOS2—bile duct cancer	2.59e-05	0.00022	CbGpPWpGaD
Gefitinib—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—bile duct cancer	2.58e-05	0.000219	CbGpPWpGaD
Gefitinib—EGFR—Axon guidance—IL6—bile duct cancer	2.58e-05	0.000218	CbGpPWpGaD
Gefitinib—IRAK1—Innate Immune System—HRAS—bile duct cancer	2.54e-05	0.000215	CbGpPWpGaD
Gefitinib—CSNK1E—Disease—KRAS—bile duct cancer	2.53e-05	0.000214	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—IDH1—bile duct cancer	2.52e-05	0.000214	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—IDH1—bile duct cancer	2.46e-05	0.000208	CbGpPWpGaD
Gefitinib—MKNK1—Signaling Pathways—TGFB1—bile duct cancer	2.46e-05	0.000208	CbGpPWpGaD
Gefitinib—EGFR—Developmental Biology—TGFB1—bile duct cancer	2.44e-05	0.000207	CbGpPWpGaD
Gefitinib—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—bile duct cancer	2.44e-05	0.000207	CbGpPWpGaD
Gefitinib—IRAK1—Innate Immune System—IL6—bile duct cancer	2.43e-05	0.000206	CbGpPWpGaD
Gefitinib—ERBB3—Immune System—NRAS—bile duct cancer	2.43e-05	0.000206	CbGpPWpGaD
Gefitinib—MKNK1—Signaling Pathways—EGFR—bile duct cancer	2.41e-05	0.000204	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—GNAS—bile duct cancer	2.33e-05	0.000198	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—MMP9—bile duct cancer	2.32e-05	0.000197	CbGpPWpGaD
Gefitinib—EGFR—Innate Immune System—NRAS—bile duct cancer	2.32e-05	0.000196	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—IDH1—bile duct cancer	2.32e-05	0.000196	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—IDH1—bile duct cancer	2.3e-05	0.000195	CbGpPWpGaD
Gefitinib—MKNK1—Signaling Pathways—KRAS—bile duct cancer	2.28e-05	0.000193	CbGpPWpGaD
Gefitinib—EGFR—Developmental Biology—KRAS—bile duct cancer	2.26e-05	0.000191	CbGpPWpGaD
Gefitinib—ERBB3—Disease—NRAS—bile duct cancer	2.24e-05	0.00019	CbGpPWpGaD
Gefitinib—EGFR—Adaptive Immune System—NRAS—bile duct cancer	2.23e-05	0.000189	CbGpPWpGaD
Gefitinib—IRAK4—Immune System—HRAS—bile duct cancer	2.23e-05	0.000189	CbGpPWpGaD
Gefitinib—ERBB3—Immune System—EGFR—bile duct cancer	2.21e-05	0.000187	CbGpPWpGaD
Gefitinib—EGFR—Disease—NOS2—bile duct cancer	2.18e-05	0.000185	CbGpPWpGaD
Gefitinib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—bile duct cancer	2.17e-05	0.000184	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—TGFBR2—bile duct cancer	2.17e-05	0.000184	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—SLC5A5—bile duct cancer	2.15e-05	0.000182	CbGpPWpGaD
Gefitinib—CSNK1E—Disease—HRAS—bile duct cancer	2.15e-05	0.000182	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—ERBB2—bile duct cancer	2.14e-05	0.000181	CbGpPWpGaD
Gefitinib—IRAK4—Immune System—IL6—bile duct cancer	2.13e-05	0.000181	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—GNAS—bile duct cancer	2.09e-05	0.000177	CbGpPWpGaD
Gefitinib—ERBB3—Immune System—KRAS—bile duct cancer	2.09e-05	0.000177	CbGpPWpGaD
Gefitinib—ERBB3—Disease—TGFB1—bile duct cancer	2.08e-05	0.000176	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—ERBB2—bile duct cancer	2.06e-05	0.000175	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—NRAS—bile duct cancer	2.06e-05	0.000174	CbGpPWpGaD
Gefitinib—CSNK1E—Disease—IL6—bile duct cancer	2.06e-05	0.000174	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—SMAD4—bile duct cancer	2.05e-05	0.000174	CbGpPWpGaD
Gefitinib—ERBB3—Disease—EGFR—bile duct cancer	2.04e-05	0.000173	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—SLC5A5—bile duct cancer	2.03e-05	0.000172	CbGpPWpGaD
Gefitinib—MKNK1—Signaling Pathways—TP53—bile duct cancer	2.02e-05	0.000172	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—NRAS—bile duct cancer	2.02e-05	0.000171	CbGpPWpGaD
Gefitinib—EGFR—Innate Immune System—KRAS—bile duct cancer	2e-05	0.000169	CbGpPWpGaD
Gefitinib—MKNK1—Signaling Pathways—HRAS—bile duct cancer	1.94e-05	0.000164	CbGpPWpGaD
Gefitinib—ERBB3—Disease—KRAS—bile duct cancer	1.93e-05	0.000163	CbGpPWpGaD
Gefitinib—EGFR—Developmental Biology—HRAS—bile duct cancer	1.92e-05	0.000163	CbGpPWpGaD
Gefitinib—EGFR—Adaptive Immune System—KRAS—bile duct cancer	1.92e-05	0.000162	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—TGFB1—bile duct cancer	1.91e-05	0.000162	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism of lipids and lipoproteins—PTGS2—bile duct cancer	1.9e-05	0.000161	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—EGFR—bile duct cancer	1.88e-05	0.000159	CbGpPWpGaD
Gefitinib—MKNK1—Signaling Pathways—IL6—bile duct cancer	1.85e-05	0.000157	CbGpPWpGaD
Gefitinib—ALB—Metabolism—SLC5A5—bile duct cancer	1.85e-05	0.000157	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—EGFR—bile duct cancer	1.84e-05	0.000156	CbGpPWpGaD
Gefitinib—EGFR—Developmental Biology—IL6—bile duct cancer	1.84e-05	0.000156	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—MMP9—bile duct cancer	1.83e-05	0.000155	CbGpPWpGaD
Gefitinib—EGFR—Immune System—ERBB2—bile duct cancer	1.78e-05	0.00015	CbGpPWpGaD
Gefitinib—ERBB3—Immune System—HRAS—bile duct cancer	1.77e-05	0.00015	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—KRAS—bile duct cancer	1.77e-05	0.00015	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—MMP9—bile duct cancer	1.77e-05	0.00015	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—IDH2—bile duct cancer	1.76e-05	0.000149	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—KRAS—bile duct cancer	1.74e-05	0.000147	CbGpPWpGaD
Gefitinib—ALB—Metabolism of lipids and lipoproteins—PTGS2—bile duct cancer	1.74e-05	0.000147	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—ERBB2—bile duct cancer	1.72e-05	0.000145	CbGpPWpGaD
Gefitinib—ERBB3—Immune System—IL6—bile duct cancer	1.7e-05	0.000144	CbGpPWpGaD
Gefitinib—EGFR—Innate Immune System—HRAS—bile duct cancer	1.7e-05	0.000144	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—GNAS—bile duct cancer	1.67e-05	0.000142	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—SLC5A5—bile duct cancer	1.66e-05	0.000141	CbGpPWpGaD
Gefitinib—EGFR—Disease—ERBB2—bile duct cancer	1.64e-05	0.000139	CbGpPWpGaD
Gefitinib—ERBB3—Disease—HRAS—bile duct cancer	1.64e-05	0.000139	CbGpPWpGaD
Gefitinib—EGFR—Adaptive Immune System—HRAS—bile duct cancer	1.63e-05	0.000138	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—NRAS—bile duct cancer	1.63e-05	0.000138	CbGpPWpGaD
Gefitinib—EGFR—Innate Immune System—IL6—bile duct cancer	1.62e-05	0.000138	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—SLC5A5—bile duct cancer	1.62e-05	0.000138	CbGpPWpGaD
Gefitinib—EGFR—Disease—PTGS2—bile duct cancer	1.6e-05	0.000136	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—GNAS—bile duct cancer	1.58e-05	0.000134	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—TP53—bile duct cancer	1.57e-05	0.000133	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—NRAS—bile duct cancer	1.57e-05	0.000133	CbGpPWpGaD
Gefitinib—ERBB3—Disease—IL6—bile duct cancer	1.57e-05	0.000133	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—bile duct cancer	1.56e-05	0.000132	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—SLC5A5—bile duct cancer	1.53e-05	0.00013	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—SLC5A5—bile duct cancer	1.52e-05	0.000128	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—IDH1—bile duct cancer	1.52e-05	0.000128	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—TGFB1—bile duct cancer	1.51e-05	0.000128	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—HRAS—bile duct cancer	1.51e-05	0.000128	CbGpPWpGaD
Gefitinib—ALB—Hemostasis—NRAS—bile duct cancer	1.48e-05	0.000126	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—EGFR—bile duct cancer	1.48e-05	0.000126	CbGpPWpGaD
Gefitinib—EGFR—Signaling by GPCR—NRAS—bile duct cancer	1.48e-05	0.000125	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—HRAS—bile duct cancer	1.48e-05	0.000125	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—MMP9—bile duct cancer	1.47e-05	0.000125	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—TGFB1—bile duct cancer	1.46e-05	0.000123	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—IL6—bile duct cancer	1.44e-05	0.000122	CbGpPWpGaD
Gefitinib—ALB—Metabolism—GNAS—bile duct cancer	1.44e-05	0.000122	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—EGFR—bile duct cancer	1.43e-05	0.000121	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—bile duct cancer	1.42e-05	0.00012	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—IL6—bile duct cancer	1.41e-05	0.00012	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—KRAS—bile duct cancer	1.4e-05	0.000119	CbGpPWpGaD
Gefitinib—ALB—Hemostasis—TGFB1—bile duct cancer	1.38e-05	0.000117	CbGpPWpGaD
Gefitinib—EGFR—Immune System—NRAS—bile duct cancer	1.35e-05	0.000114	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—KRAS—bile duct cancer	1.35e-05	0.000114	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—NRAS—bile duct cancer	1.31e-05	0.000111	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—GNAS—bile duct cancer	1.29e-05	0.00011	CbGpPWpGaD
Gefitinib—ALB—Hemostasis—KRAS—bile duct cancer	1.28e-05	0.000108	CbGpPWpGaD
Gefitinib—EGFR—Signaling by GPCR—KRAS—bile duct cancer	1.27e-05	0.000108	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—GNAS—bile duct cancer	1.26e-05	0.000107	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—PTGS2—bile duct cancer	1.25e-05	0.000106	CbGpPWpGaD
Gefitinib—EGFR—Disease—NRAS—bile duct cancer	1.25e-05	0.000106	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—TP53—bile duct cancer	1.24e-05	0.000105	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—TGFB1—bile duct cancer	1.21e-05	0.000103	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—TP53—bile duct cancer	1.2e-05	0.000102	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—HRAS—bile duct cancer	1.19e-05	0.000101	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—EGFR—bile duct cancer	1.19e-05	0.000101	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—GNAS—bile duct cancer	1.19e-05	0.000101	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—GNAS—bile duct cancer	1.18e-05	9.99e-05	CbGpPWpGaD
Gefitinib—EGFR—Immune System—KRAS—bile duct cancer	1.16e-05	9.85e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—TGFB1—bile duct cancer	1.16e-05	9.82e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—ERBB2—bile duct cancer	1.15e-05	9.73e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—HRAS—bile duct cancer	1.15e-05	9.72e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—IL6—bile duct cancer	1.14e-05	9.65e-05	CbGpPWpGaD
Gefitinib—ALB—Hemostasis—TP53—bile duct cancer	1.13e-05	9.62e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—KRAS—bile duct cancer	1.12e-05	9.52e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—IL6—bile duct cancer	1.1e-05	9.31e-05	CbGpPWpGaD
Gefitinib—ALB—Hemostasis—HRAS—bile duct cancer	1.09e-05	9.2e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling by GPCR—HRAS—bile duct cancer	1.08e-05	9.16e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—KRAS—bile duct cancer	1.07e-05	9.09e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling by GPCR—IL6—bile duct cancer	1.03e-05	8.77e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—SLC5A5—bile duct cancer	1e-05	8.47e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—TP53—bile duct cancer	9.99e-06	8.46e-05	CbGpPWpGaD
Gefitinib—EGFR—Immune System—HRAS—bile duct cancer	9.88e-06	8.37e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—MMP9—bile duct cancer	9.84e-06	8.34e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—HRAS—bile duct cancer	9.55e-06	8.09e-05	CbGpPWpGaD
Gefitinib—EGFR—Immune System—IL6—bile duct cancer	9.46e-06	8.01e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—IL6—bile duct cancer	9.14e-06	7.75e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—HRAS—bile duct cancer	9.12e-06	7.73e-05	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—PTGS2—bile duct cancer	8.98e-06	7.61e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—NRAS—bile duct cancer	8.73e-06	7.4e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—IL6—bile duct cancer	8.73e-06	7.4e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—PTGS2—bile duct cancer	8.48e-06	7.19e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—TGFB1—bile duct cancer	8.11e-06	6.88e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—GNAS—bile duct cancer	7.77e-06	6.59e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—PTGS2—bile duct cancer	7.73e-06	6.55e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—KRAS—bile duct cancer	7.51e-06	6.37e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—PTGS2—bile duct cancer	6.94e-06	5.88e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—PTGS2—bile duct cancer	6.77e-06	5.74e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—TP53—bile duct cancer	6.68e-06	5.66e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—HRAS—bile duct cancer	6.39e-06	5.41e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—PTGS2—bile duct cancer	6.38e-06	5.41e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—PTGS2—bile duct cancer	6.33e-06	5.36e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—IL6—bile duct cancer	6.11e-06	5.18e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—PTGS2—bile duct cancer	4.17e-06	3.54e-05	CbGpPWpGaD
